Chromatin regulators and stratify prostate cancer risk and reveal -driven progression via PI3K/AKT pathway.
1/5 보강
[OBJECTIVE] To identify chromatin regulators (CRs)-based molecular subtypes and risk scores for accurately predicting biochemical recurrence (BCR) after radical prostatectomy (RAP) in prostate cancer
- p-value P=0.003
- p-value P=0.010
- 95% CI 1.05-4.02
- HR 2.05
APA
Wang Z, Wang J, et al. (2026). Chromatin regulators and stratify prostate cancer risk and reveal -driven progression via PI3K/AKT pathway.. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 38(1), 83-99. https://doi.org/10.21147/j.issn.1000-9604.2026.01.06
MLA
Wang Z, et al.. "Chromatin regulators and stratify prostate cancer risk and reveal -driven progression via PI3K/AKT pathway.." Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, vol. 38, no. 1, 2026, pp. 83-99.
PMID
41852923 ↗
Abstract 한글 요약
[OBJECTIVE] To identify chromatin regulators (CRs)-based molecular subtypes and risk scores for accurately predicting biochemical recurrence (BCR) after radical prostatectomy (RAP) in prostate cancer (PCa) patients.
[METHODS] Differentially expressed genes (DEGs) between tumor and normal samples from The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) databases were intersected with CR-related and prognostic genes. Consensus clustering, risk score analysis, functional analysis, immune microenvironment, m6A, and heterogeneity assessments were performed using R software. validation used DU145 and C42B PCa cell lines. Topoisomerase II alpha () was knocked down via siRNA. Assays included CCK-8 proliferation, colony formation, transwell migration/invasion, wound healing, and western blotting (WB) for pathway validation.
[RESULTS] and peroxisome proliferator-activated receptor gamma coactivator 1-alpha () defined molecular subtypes and a risk score in TCGA, validated in a GEO dataset. Cluster 2 exhibited significantly shorter BCR-free survival . cluster 1 in TCGA [hazard ratio (HR): 2.21; 95% confidence interval (95% CI): 1.32-3.73; P=0.003)], GEO (HR: 2.05; 95% CI: 1.05-4.02; P=0.010), and MSKCC2010 (HR: 5.93; 95% CI: 1.96-17.87; P<0.001). Similar survival differences were observed between high- and low-risk groups (defined by the median risk score). Cluster 2 showed greater tumor heterogeneity and higher m6A gene expression. Gene set variation analysis (GSVA) revealed downregulated cell-cycle pathways in cluster 2, alongside suppressed tumor-infiltrating immune cells. knockdown significantly impaired PCa cell proliferation, colony formation, migration, and invasion. Mechanistically, it suppressed phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway activation, reducing phosphorylated PI3K and AKT levels without altering total protein.
[CONCLUSIONS] and effectively stratify PCa subtypes for RAP patients. TOP2A drives malignant progression via the PI3K/AKT pathway.
[METHODS] Differentially expressed genes (DEGs) between tumor and normal samples from The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) databases were intersected with CR-related and prognostic genes. Consensus clustering, risk score analysis, functional analysis, immune microenvironment, m6A, and heterogeneity assessments were performed using R software. validation used DU145 and C42B PCa cell lines. Topoisomerase II alpha () was knocked down via siRNA. Assays included CCK-8 proliferation, colony formation, transwell migration/invasion, wound healing, and western blotting (WB) for pathway validation.
[RESULTS] and peroxisome proliferator-activated receptor gamma coactivator 1-alpha () defined molecular subtypes and a risk score in TCGA, validated in a GEO dataset. Cluster 2 exhibited significantly shorter BCR-free survival . cluster 1 in TCGA [hazard ratio (HR): 2.21; 95% confidence interval (95% CI): 1.32-3.73; P=0.003)], GEO (HR: 2.05; 95% CI: 1.05-4.02; P=0.010), and MSKCC2010 (HR: 5.93; 95% CI: 1.96-17.87; P<0.001). Similar survival differences were observed between high- and low-risk groups (defined by the median risk score). Cluster 2 showed greater tumor heterogeneity and higher m6A gene expression. Gene set variation analysis (GSVA) revealed downregulated cell-cycle pathways in cluster 2, alongside suppressed tumor-infiltrating immune cells. knockdown significantly impaired PCa cell proliferation, colony formation, migration, and invasion. Mechanistically, it suppressed phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway activation, reducing phosphorylated PI3K and AKT levels without altering total protein.
[CONCLUSIONS] and effectively stratify PCa subtypes for RAP patients. TOP2A drives malignant progression via the PI3K/AKT pathway.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Flap perfusion assessment with indocyanine green angiography in deep inferior epigastric perforator flap breast reconstruction: A systematic review and meta-analysis.
- A case of pulmonary mucosa-associated lymphoid tissue lymphoma with plasmacytic differentiation and amyloid deposition: case report and literature review.
- Role of ferroptosis and autophagy in pulmonary diseases.
- NUP62 Elevates USP10 Expression and Promotes Tamoxifen Resistance of Breast Cancer by Deubiquitinating ERα.
- Multi-omics analysis identifies a glycosyltransferase-related prognostic signature linked to the immune landscape in colorectal cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.